Last edition
News about "German life sciences major Bayer"
Bayer Targets Return to Mid-Single-Digit Pharma Growth by 2027
Addressing investors at a major healthcare conference, Stefan Oelrich, head of Bayer’s pharmaceuticals business, said the company expects 2026 to be the final year significantly affected by the loss of exclusivity on its blockbuster anticoagulant Xarelto. From 2027 onward, Bayer anticipates a recovery driven by newer medicines and pipeline progress.
German Life Sciences Major Bayer | 14/01/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy